Core Viewpoint - The field of automated low-temperature storage for biological samples is experiencing a new surge due to the rapid development of cell therapy and precision medicine, positioning it as a key component of the life sciences "new infrastructure" [2][5]. Company Overview - Shanghai Yuaneng Cell Biology Low-Temperature Equipment Co., Ltd. (Yuaneng Biology) has initiated a Series B financing round with a target of 200 million yuan and plans to go public on the Sci-Tech Innovation Board in two years [2][5]. - The company, founded in 2017, specializes in the research, design, and manufacturing of automated low-temperature storage equipment for biological samples, covering various temperature ranges from -196°C to 8°C [7][10]. Market Potential - The biological sample low-temperature storage sector is still in its early stages, with the market size expected to reach hundreds of billions in the next 5-10 years due to equipment upgrades and new demand [5][12]. - The market share of biological sample banks in the medical low-temperature storage market has exceeded 30% [12]. Technological Innovations - Yuaneng Biology has developed a "hive-style" independent storage structure that eliminates cross-contamination and ensures permanent independent storage of samples, which is crucial for virus sample preservation [8][10]. - The company has introduced a vacuum negative pressure single-tube picking technology that minimizes sample damage and maintains a low activity loss rate of less than 0.3%, outperforming industry averages [10][11]. Product Development and Recognition - Yuaneng Biology's products have received multiple international certifications, including the world's first intelligent deep low-temperature biological sample library and a dual-mode intelligent ultra-low temperature biological sample library [11]. - The Orcella duo™ 1100S automated ultra-low temperature storage system won the "Outstanding New Product Award" from the International Society for Biological and Environmental Repositories (ISBER) in 2025 [11]. Business Strategy - The company is shifting from a "single equipment sales" model to a comprehensive solution covering the entire chain from sample preparation to application [12][14]. - Yuaneng Biology aims to achieve a revenue of 1.3 billion yuan by 2025, with a target of approximately 5 billion yuan by 2027, maintaining an annual growth rate of doubling revenue over the next five years [12][13]. Leadership and Vision - The founder and chairman, Qu Jianguo, emphasizes the importance of proactive health management and the potential for growth in reproductive health, anti-aging, and wellness sectors [14].